Safety and Efficacy of Sintilimab(S) in Combination With Histone Deacetylase Inhibitor (Chidamide, C) in Refractory and Relapsed (R) Angioimmunoblastic T-cell Lymphoma (AT): A Single-arm, Multicenter Phase II Study(SCRAT)
Latest Information Update: 20 Apr 2023
At a glance
- Drugs Sintilimab (Primary) ; Tucidinostat (Primary)
- Indications T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 08 Apr 2021 New trial record